Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (19,101)	$ (51,255)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	2,044	459
Shares issued for services	124	0
Research and development expensed - license acquired	192	3,000
Change in fair value of convertible notes payable	0	109
Change in fair value of warrant liability	223	16,501
Loss on warrant issuance	0	5,020
Amortization of debt discount	150	0
Changes in operating assets and liabilities from continuing operations:
Prepaid expenses and other current assets	(791)	(686)
Accounts payable	1,091	(1,424)
Accrued expenses	5	1,533
Accrued interest	0	13
Licenses payable	(4,850)	7,425
Net cash used in operating activities	(20,913)	(19,305)
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants in a private offering	0	16,520
Proceeds from issuance of common stock, net of issuance costs	8,850	0
Proceeds from issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs	6,365	5,920
Proceeds from issuance of common stock and convertible notes payable, net of issuance costs	10,907	0
Proceeds from note payable	147	0
Proceeds from issuance of common stock in at-the-market offering	0	2,567
Proceeds from exercise of warrants	45	4,517
Net cash provided by financing activities	26,314	29,524
Cash flows from discontinued operations:
Net increase in cash	5,401	10,219
Cash, beginning of period	10,261	42
Cash, end of period	15,662	10,261
Supplemental disclosure of cash flow information:
Cash paid for interest	11	16
Cash paid for income taxes	0	0
Non-cash investing and financing activities:
Issuance of common stock for license payable	2,443	0
Issuance of common stock for conversion of debt	0	2,551
Issuance of common stock for conversion of accrued interest	0	164
Issuance of common stock for license acquired	0	3,000
Effect of reverse merger	0	299
Reclass of warrant liabilities related to Series A warrants exercised for cash	124	5,600
Reclass of Series B warrants from warrant liability to stockholders' equity	$ 0	$ 31,473